NCT03250377

A Study to Test the Safety/ Efficacy of Brivaracetam (BRV) Used as Adjunctive Treatment in Subjects >=16 Years of Age With Partial Seizures With or Without Secondary Generalization

An Open-Label, Multicenter, Follow-up Study to Evaluate the Long-Term Safety and Efficacy of Brivaracetam Used as Adjunctive Treatment in Subjects >=16 Years of Age With Partial Seizures With or Without Secondary Generalization

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 207 (actual)
• Sponsor: UCB Biopharma SRL · Industry
• Sex: All
• Age: 16 Years
• Healthy volunteers: Not accepted

Summary

The purpose of the study is to evaluate the long-term safety and tolerability of Brivaracetam (BRV) in focal epilepsy subjects with partial seizures and to evaluate the maintenance of efficacy of BRV over time.

Conditions

• Partial Seizures With or Without Secondary Generalization
• Epilepsy

Interventions

Type	Name	Description
DRUG	Brivaracetam	* Pharmaceutical form: Film-coated tablet * Concentration: 25 mg and 50 mg * Route of administration: Oral use

Timeline

• Start date: 2017-08-05
• Primary completion: 2024-12-24
• Completion: 2024-12-24
• First posted: 2017-08-15
• Last updated: 2025-07-29
• Results posted: 2025-07-29

Locations

59 sites across 2 countries: China, Japan